19 June 2013
Keywords: bayer, presents, results, xarelto, trial, aha, germany
Article | 17 November 2008
Germany's Bayer Schering Pharma presented findings from a Phase II study of the novel oral anticoagulant Xarelto (rivaroxaban) as a ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
17 November 2008
24 November 2008
18 June 2013
© 2013 thepharmaletter.com